摘要
In a recent study published in Nature Biotechnology,1 Nahmad and colleagues reported in vivo B-cell engineering to generate broadly neutralizing antibodies(bnAbs)against human immunodeficiency virus type 1(HIV-1)in mice.This proof-of-concept study suggests the possibility of in vivo B-cell engineering as a novel preventive or therapeutic approach against HIV-1 infection.
基金
This work was supported by the National Natural Science Foundation of China(82271786,81971927)
the Science and Technology Planning Project of Shenzhen City(20190804095916056,JCYJ20200109142601702)
Youth Program of Chinese Academy of Sciences(E1BDEDF7241).
